Key facts
- This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Nov 2023, 19:41.
Eric Devroe - 14 Nov 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ACRV
- Reported as of
- 14 Nov 2023
- Net transaction value
- -$12,446
- SEC form
- 4
- Accepted by SEC
- 16 Nov 2023, 19:41:32 UTC
- Prior SEC filing
- 06 Jun 2023
- Next SEC filing
- 16 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 16 Nov 2023.
Change
- Previous filing in this sequence was filed on 06 Jun 2023.
- Current net transaction value: -$12,446.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRV
transaction
Common Stock
Tax liability
- Transaction value
- $12,446
- Shares
- -2,450
- Change %
- -3.9%
- Price
- $5.08
- Shares after
- 60,433
- Date
- 14 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.